Atom Investors’s Krystal Biotech KRYS Stock Holding History

Atom Investors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,002	Closed	-$580K	–	508
2023 Q3	$580K	Buy	+5,002	New	+$610K	0.13%	205
2020 Q3	–	Sell	-29,117	Closed	-$1.21M	–	565
2020 Q2	$1.21M	Sell	29,117 -19,084	-40%	-$918K	0.08%	194
2020 Q1	$2.08M	Buy	+48,201	New	+$2.52M	0.18%	107

Other funds holding KRYS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Atom Investors's KRYS Position: Q4 2023 in Review

Atom Investors sold out of Krystal Biotech (KRYS) in Q4 2023, closing a stake of 5,002 shares — an estimated $580K sold.

Atom Investors first reported a position in KRYS in Q1 2020 and held it in 3 quarters. The position peaked at $2.08M in Q1 2020. 194 funds tracked by Wall St. Rank hold KRYS as of Q4 2023.

Atom Investors reported no remaining Krystal Biotech position as of Q4 2023 after selling out during the quarter.
Atom Investors sold 5,002 Krystal Biotech shares in Q4 2023, an estimated $580K.
Atom Investors first reported a position in Krystal Biotech in Q1 2020 and held it in 3 quarters.
Atom Investors's Krystal Biotech position peaked at $2.08M in Q1 2020.
194 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2023.

Based on Atom Investors's 13F filing for Q4 2023, filed 14 Feb 2024.